September, 2025
September 2025
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Tracey O’Brien: A Privilege to Speak at the Rare Cancers Australia Forum at Parliament House, Canberra
Sep 2, 2025, 12:08

Tracey O’Brien: A Privilege to Speak at the Rare Cancers Australia Forum at Parliament House, Canberra

Tracey O’Brien, Chief Cancer Officer and CEO of Cancer Institute NSW, shared a post by Rare Cancers Australia on LinkedIn:

“A privilege to speak today at the Rare Cancers Australia Forum at Parliament House, Canberra.

Rare cancers account for 1 in 4 diagnoses — yet they cause 1 in 3 cancer deaths. For patients and their carers, the journey is often harder: limited access to life-saving genomics, innovative therapies, and the data needed to drive better care.

Led with passion by Christine Cockburn, powerful advocacy is happening — alongside patients and clinicians — to push for fairer drug access, genomic funding, and stronger data systems. Their goal is simple but profound: that people with rare cancers are heard, valued, and given the same chance at life as those with more common cancers.”

Quoting Rare Cancers Australia’s post:

“Session 2 of CanForum began with Kevin M. , who offered his deeply personal perspective of becoming a carer for his wife Caitlin – sharing impacts on his family and their financial stability. He shared the need for carers to be counted as a vital part of the care team, and have the support they need, too.

Professor Tracey O’Brien, AM spoke about how work in NSW to really take the time to listen to patients is shaping cancer care.

Our panel discussion explored the potential of personalised treatments, through comprehensive genomic profiling and personalised mRNA vaccines.

The session closed with Lilly’s President of North Asia-Pacific and General Manager Australia and New Zealand, Tori Brown, who explained why access to cancer treatments is personal to her – and should be to all of us.”

More posts featuring Tracey O’Brien and Rare Cancers Australia on OncoDaily.